Clearmind Medicine Inc.
CMND.CN
Canadian Securities Exchange1.60
CAD
-0.23
- -
ISIN
CA1850534027
Return %
Stock
S&P500
1Y
-92.38
26.53
3Y
-99.04
76.60
5Y
-98.22
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Adi Zuloff-Shani
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1220 West 6th Avenue Vancouver BC Canada V6H 1A5
- IPO Date
- May 29, 2018
- Website
- clearmindmedicine.com
- Similar Companies
- Business
- Clearmind Medicine Inc. (Nasdaq: CMND; FSE: CWY0) is a clinical-stage psychedelic pharmaceutical biotech company that discovers and develops novel non-hallucinogenic neuroplastogen-derived therapeutics to address underserved mental health and addiction disorders, including alcohol use disorder (AUD), binge eating disorder, depression, cocaine addiction, and post-traumatic stress disorder (PTSD); its lead product candidate is CMND-100, a proprietary oral MEAI (5-Methoxy-2-aminoindane)-based therapy targeting AUD by modulating serotonin and dopamine pathways to reduce cravings and consumption, with additional pipeline assets including MEAI combined with CannAmide for AUD, 2-Fluorodeschloroketamine for major depressive disorder, Palmidrol for AUD, and collaborative developments for binge behaviors; the company holds 19 patent families encompassing 31 granted patents and seeks further intellectual property protection. Founded in 2017 and headquartered in Vancouver, British Columbia, Canada, Clearmind operates primarily in North America and Israel, conducting multinational Phase I/IIa clinical trials for CMND-100 at leading sites including Yale School of Medicine, Johns Hopkins University School of Medicine, Hadassah Medical Center, and Tel Aviv Sourasky Medical Center. Recent developments include securing a $10 million securities purchase agreement with institutional investors in September 2025 to fund working capital, general corporate purposes, and strategic opportunities such as potential acquisitions; completing treatment of the first cohort and reporting positive top-line safety and tolerability results in October-November 2025; receiving unanimous Data and Safety Monitoring Board approval to continue the FDA-regulated Phase I/IIa trial in November 2025; expanding trial sites with final approval at Hadassah and activation at Tel Aviv Sourasky; filing U.S. and Israeli patent applications for MEAI in cocaine addiction and non-hallucinogenic depression treatments; partnering with SciSparc's Neurothera Labs on an Israeli patent for binge behavior therapies; and engaging a leading U.S. government affairs firm in June 2025 to advocate for psychedelic regulatory frameworks.